Investor
RA CAPITAL MANAGEMENT, L.P.
CIK 0001346824 · filed 2026-05-15 · SEC filing
13F book
$9.44B
Positions
85
24 new · 10 sold
Largest name
24.9%
Ascendis Pharma A/S · ASND
Est. mark
$3.2M
Price effect on 61 names still held. Flow −$326.3M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/S | ASND | 10.3M | $2.35B | 24.9% | $159.3M | Held |
| Vaxcyte, Inc. | PCVX | 11.5M | $666.8M | 7.1% | $128.4M | Added$172M |
| Rhythm Pharmaceuticals, Inc. | RYTM | 6.67M | $579.8M | 6.1% | −$133.8M | Held |
| Tyra Biosciences, Inc. | TYRA | 12.2M | $467.2M | 5.0% | $146.5M | Held |
| Sionna Therapeutics, Inc. | SION | 9.91M | $397.1M | 4.2% | −$10.4M | Held |
| Edgewise Therapeutics, Inc. | EWTX | 10.4M | $328.5M | 3.5% | $69.7M | Held |
| Newamsterdam Pharma Company | — | 9.55M | $305.7M | 3.2% | −$29.3M | Held |
| Nuvalent Inc | — | 2.53M | $259.6M | 2.8% | $3.5M | Added$70.5M |
| Dianthus Therapeutics Inc | — | 2.61M | $219.2M | 2.3% | $68.8M | Added$152.8M |
| Mineralys Therapeutics, Inc. | MLYS | 7.69M | $208.4M | 2.2% | −$67.4M | Added−$57.4M |
| SpyGlass Pharma, Inc. | SGP | 8.02M | $207.8M | 2.2% | — | New |
| Wave Life Sciences Ltd. | WVE | 27M | $195.6M | 2.1% | −$177.5M | Added−$113.9M |
| Septerna, Inc. | SEPN | 7M | $168.1M | 1.8% | −$26.9M | Held |
| Disc Medicine, Inc. | IRON | 2.45M | $156.7M | 1.7% | −$30.6M | Added−$257.5K |
| Janux Therapeutics, Inc. | JANX | 11.2M | $155.5M | 1.6% | $1.12M | Held |
| Biocryst Pharmaceuticals Inc | BCRX | 15.8M | $150.7M | 1.6% | $27.2M | Held |
| Bicara Therapeutics Inc. | BCAX | 7.26M | $144.3M | 1.5% | $21.3M | Added$27.3M |
| Praxis Precision Medicines I | — | 373.8K | $120.4M | 1.3% | $10.3M | Held |
| Gh Research Plc | GHRS | 7.68M | $107.9M | 1.1% | $10.4M | Held |
| Zai Lab Ltd | ZLAB | 5.71M | $107.4M | 1.1% | — | New |
| Taysha Gene Therapies, Inc. | TSHA | 23.6M | $105.3M | 1.1% | −$24.3M | Held |
| Vor Biopharma Inc. | VOR | 5.4M | $96.4M | 1.0% | $25.7M | Held |
| Geron Corp | GERN | 63.8M | $95M | 1.0% | $10.8M | Held |
| ARS Pharmaceuticals, Inc. | SPRY | 10.9M | $87.2M | 0.9% | −$39.3M | Held |
| Sarepta Therapeutics, Inc. | SRPT | 3.9M | $84.9M | 0.9% | — | New |
| Spyre Therapeutics, Inc. | SYRE | 1.62M | $81.8M | 0.9% | $28.7M | Held |
| Evommune, Inc. | EVMN | 3.49M | $80.3M | 0.9% | $20.3M | Added$21.1M |
| Climb Bio, Inc. | CLYM | 11.3M | $77.4M | 0.8% | −$348.5K | Added−$299.8K |
| Solid Biosciences Inc. | SLDB | 9.34M | $67.2M | 0.7% | $9.07M | Added$34.5M |
| Artiva Biotherapeutics, Inc. | ARTV | 9.85M | $63.5M | 0.7% | $21.2M | Held |
| Galecto Inc | DMRA | 2.4M | $62.1M | 0.7% | — | New |
| Xencor Inc | XNCR | 4.9M | $59.1M | 0.6% | — | New |
| Lb Pharmaceuticals Inc | LBRX | 2.21M | $54.5M | 0.6% | $5.3M | Held |
| Jade Biosciences, Inc. | JBIO | 3.67M | $51.6M | 0.5% | −$5.07M | Held |
| Acumen Pharmaceuticals, Inc. | ABOS | 21M | $49.5M | 0.5% | $3.73M | Added$18M |
| 4d Molecular Therapeutics In | — | 5.05M | $47M | 0.5% | $9.14M | Cut$4.61M |
| Fulcrum Therapeutics, Inc. | FULC | 6.05M | $46.4M | 0.5% | −$22M | Held |
| Capricor Therapeutics, Inc. | CAPR | 1.51M | $45.8M | 0.5% | $2.32M | Held |
| Century Therapeutics, Inc. | IPSC | 17.8M | $40.1M | 0.4% | — | New |
| Olema Pharmaceuticals, Inc. | OLMA | 2.6M | $38.8M | 0.4% | −$26.2M | Held |
| LENZ Therapeutics, Inc. | LENZ | 4.18M | $38.2M | 0.4% | −$28.6M | Held |
| Monopar Therapeutics | MNPR | 667.2K | $36.6M | 0.4% | −$7.01M | Held |
| PepGen Inc. | PEPG | 20.1M | $35.5M | 0.4% | −$95.1M | Held |
| Design Therapeutics, Inc. | DSGN | 2.97M | $31.6M | 0.3% | $1.84M | Added$17.9M |
| Mirum Pharmaceuticals, Inc. | MIRM | 318.6K | $29.4M | 0.3% | — | New |
| BioAge Labs, Inc. | BIOA | 1.65M | $28.9M | 0.3% | — | New |
| Lexeo Therapeutics, Inc. | LXEO | 5M | $28.7M | 0.3% | −$20.9M | Held |
| Assembly Biosciences, Inc. | ASMB | 1.02M | $28.3M | 0.3% | −$6.39M | Held |
| Rezolute, Inc. | RZLT | 9.18M | $28M | 0.3% | $6.33M | Held |
| Aktis Oncology, Inc. | AKTS | 1.5M | $26.9M | 0.3% | — | New |
| Alx Oncology Hldgs Inc | — | 13M | $26.1M | 0.3% | — | New |
| Aclaris Therapeutics, Inc. | ACRS | 6.8M | $25.5M | 0.3% | — | New |
| Ovid Therapeutics Inc. | OVID | 10.7M | $23.8M | 0.3% | $6.32M | Held |
| Nkarta, Inc. | NKTX | 10.8M | $22.8M | 0.2% | $2.81M | Held |
| Travere Therapeutics, Inc. | TVTX | 746.8K | $22.2M | 0.2% | — | New |
| GRAIL, Inc. | GRAL | 428.3K | $22.1M | 0.2% | −$14.5M | Held |
| C4 Therapeutics, Inc. | CCCC | 8M | $21M | 0.2% | $5.76M | Held |
| Relmada Therapeutics, Inc. | RLMD | 2.95M | $20.5M | 0.2% | — | New |
| Benitec Biopharma Inc. | BNTC | 1.85M | $19.7M | 0.2% | −$5.22M | Held |
| Bright Minds Biosciences Inc. | DRUG | 265K | $19.3M | 0.2% | — | New |
| Sutro Biopharma, Inc. | STRO | 715.3K | $17.8M | 0.2% | — | New |
| Contineum Therapeutics, Inc. | CTNM | 1.3M | $16.9M | 0.2% | $2.11M | Cut−$7.99M |
| Sab Biotherapeutics Inc | — | 4.4M | $16.9M | 0.2% | $396.1K | Held |
| Inspire Med Sys Inc | — | 325.7K | $16.8M | 0.2% | −$5.77M | Added$3.7M |
| Anteris Technologies Global Corp. | AVR | 3M | $16.6M | 0.2% | — | New |
| OnKure Therapeutics, Inc. | OKUR | 4M | $16.6M | 0.2% | — | New |
| Hinge Health, Inc. | HNGE | 364.6K | $14.1M | 0.1% | −$632.1K | Added$10.3M |
| GeneDx Holdings Corp. | WGS | 209.9K | $13.5M | 0.1% | −$3.82M | Added$5.93M |
| Waystar Hldg Corp | — | 529.4K | $12.8M | 0.1% | −$1.25M | Added$8.03M |
| Helix Acquisition Corp. III | HLXC | 1.25M | $12.7M | 0.1% | — | New |
| Palisade Bio, Inc. | PALI | 7.12M | $12.5M | 0.1% | −$4.27M | Held |
| Acrivon Therapeutics, Inc. | ACRV | 8.34M | $11.6M | 0.1% | −$8.51M | Held |
| Atrium Therapeutics, Inc. | RNA | 864.1K | $11.6M | 0.1% | — | New |
| Karyopharm Therapeutics Inc. | KPTI | 1.92M | $10.7M | 0.1% | — | New |
| Avalo Therapeutics, Inc. | AVTX | 663K | $9.9M | 0.1% | −$2.14M | Held |
| Perceptive Cap Solutions Cor | — | 750K | $8.23M | 0.1% | −$1.54M | Held |
| Adicet Bio, Inc. | ACET | 1.18M | $8.05M | 0.1% | −$1.53M | Added$69.4K |
| Newamsterdam Pharma Company | — | 333.3K | $6.68M | 0.1% | −$986.7K | Held |
| Corvus Pharmaceuticals, Inc. | CRVS | 450K | $6.58M | 0.1% | — | New |
| Rani Therapeutics Hldgs Inc | — | 8.5M | $6.25M | 0.1% | −$5.23M | Held |
| Equillium, Inc. | EQ | 3.1M | $6.19M | 0.1% | — | New |
| Werewolf Therapeutics, Inc. | HOWL | 6.68M | $5.56M | 0.1% | $1.33M | Held |
| Macrogenics Inc | MGNX | 1.86M | $5.39M | 0.1% | — | New |
| MapLight Therapeutics, Inc. | MPLT | 248.3K | $5.05M | 0.1% | — | New |
| Palatin Technologies Inc | PTN | 70K | $1.22M | 0.0% | $142.8K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.